Lubomir Sokol is a Hematology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 794 publications with 12,344 citations (h-index 56); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Stemline Therapeutics Inc.Program year20241 payment
- RECORDATI_RARE_DISEASES_INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2019–2022 per NIH RePORTER. The latest:
- Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma
H. Lee Moffitt Cancer Ctr & Res Inst
FY2022$537,558R01CA240434 - Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma
H. Lee Moffitt Cancer Ctr & Res Inst
FY2021$548,529R01CA240434 - Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma
H. Lee Moffitt Cancer Ctr & Res Inst
FY2020$548,529R01CA240434
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Nikhil Khushalani, MD
Moffitt Cancer Center
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”